Literature DB >> 27277033

Dosimetric comparison of stopping power calibration with dual-energy CT and single-energy CT in proton therapy treatment planning.

Jiahua Zhu1, Scott N Penfold2.   

Abstract

PURPOSE: The accuracy of proton dose calculation is dependent on the ability to correctly characterize patient tissues with medical imaging. The most common method is to correlate computed tomography (CT) numbers obtained via single-energy CT (SECT) with proton stopping power ratio (SPR). CT numbers, however, cannot discriminate between a change in mass density and change in chemical composition of patient tissues. This limitation can have consequences on SPR calibration accuracy. Dual-energy CT (DECT) is receiving increasing interest as an alternative imaging modality for proton therapy treatment planning due to its ability to discriminate between changes in patient density and chemical composition. In the current work we use a phantom of known composition to demonstrate the dosimetric advantages of proton therapy treatment planning with DECT over SECT.
METHODS: A phantom of known composition was scanned with a clinical SECT radiotherapy CT-simulator. The phantom was rescanned at a lower X-ray tube potential to generate a complimentary DECT image set. A set of reference materials similar in composition to the phantom was used to perform a stoichiometric calibration of SECT CT number to proton SPRs. The same set of reference materials was used to perform a DECT stoichiometric calibration based on effective atomic number. The known composition of the phantom was used to assess the accuracy of SPR calibration with SECT and DECT. Intensity modulated proton therapy (IMPT) treatment plans were generated with the SECT and DECT image sets to assess the dosimetric effect of the imaging modality. Isodose difference maps and root mean square (RMS) error calculations were used to assess dose calculation accuracy.
RESULTS: SPR calculation accuracy was found to be superior, on average, with DECT relative to SECT. Maximum errors of 12.8% and 2.2% were found for SECT and DECT, respectively. Qualitative examination of dose difference maps clearly showed the dosimetric advantages of DECT imaging, compared to SECT imaging for IMPT dose calculation for the case investigated. Quantitatively, the maximum dose calculation error in the SECT plan was 7.8%, compared to a value of 1.4% in the DECT plan. When considering the high dose target region, the root mean square (RMS) error in dose calculation was 2.1% and 0.4% for SECT and DECT, respectively.
CONCLUSIONS: DECT-based proton treatment planning in a commercial treatment planning system was successfully demonstrated for the first time. DECT is an attractive imaging modality for proton therapy treatment planning owing to its ability to characterize density and chemical composition of patient tissues. SECT and DECT scans of a phantom of known composition have been used to demonstrate the dosimetric advantages obtainable in proton therapy treatment planning with DECT over the current approach based on SECT.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27277033     DOI: 10.1118/1.4948683

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  12 in total

Review 1.  Status and innovations in pre-treatment CT imaging for proton therapy.

Authors:  Patrick Wohlfahrt; Christian Richter
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

2.  Learning-based synthetic dual energy CT imaging from single energy CT for stopping power ratio calculation in proton radiation therapy.

Authors:  Serdar Charyyev; Tonghe Wang; Yang Lei; Beth Ghavidel; Jonathan J Beitler; Mark McDonald; Walter J Curran; Tian Liu; Jun Zhou; Xiaofeng Yang
Journal:  Br J Radiol       Date:  2021-10-28       Impact factor: 3.039

3.  Helium CT: Monte Carlo simulation results for an ideal source and detector with comparison to proton CT.

Authors:  Pierluigi Piersimoni; Bruce A Faddegon; José Ramos Méndez; Reinhard W Schulte; Lennart Volz; Joao Seco
Journal:  Med Phys       Date:  2018-05-20       Impact factor: 4.071

Review 4.  Proton therapy for non-small cell lung cancer: the road ahead.

Authors:  Eric D Brooks; Matthew S Ning; Vivek Verma; X Ronald Zhu; Joe Y Chang
Journal:  Transl Lung Cancer Res       Date:  2019-09

Review 5.  Imaging for Target Delineation and Treatment Planning in Radiation Oncology: Current and Emerging Techniques.

Authors:  Sonja Stieb; Brigid McDonald; Mary Gronberg; Grete May Engeseth; Renjie He; Clifton David Fuller
Journal:  Hematol Oncol Clin North Am       Date:  2019-09-17       Impact factor: 3.722

6.  Potential of a Second-Generation Dual-Layer Spectral CT for Dose Calculation in Particle Therapy Treatment Planning.

Authors:  Friderike K Longarino; Antonia Kowalewski; Thomas Tessonnier; Stewart Mein; Benjamin Ackermann; Jürgen Debus; Andrea Mairani; Wolfram Stiller
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

7.  Evaluation of Computed Tomography Scanners for Feasibility of Using Averaged Hounsfield Unit-to-Stopping Power Ratio Calibration Curve.

Authors:  Heeteak Chung; Sina Mossahebi; Arun Gopal; Giovanni Lasio; Huijun Xu; Jerimy Polf
Journal:  Int J Part Ther       Date:  2018-11-30

8.  Learning-Based Stopping Power Mapping on Dual-Energy CT for Proton Radiation Therapy.

Authors:  Tonghe Wang; Yang Lei; Joseph Harms; Beth Ghavidel; Liyong Lin; Jonathan J Beitler; Mark McDonald; Walter J Curran; Tian Liu; Jun Zhou; Xiaofeng Yang
Journal:  Int J Part Ther       Date:  2021-02-12

Review 9.  Dual-Energy CT in Head and Neck Imaging.

Authors:  Elise D Roele; Veronique C M L Timmer; Lauretta A A Vaassen; Anna M J L van Kroonenburgh; A A Postma
Journal:  Curr Radiol Rep       Date:  2017-03-29

10.  Dual-Energy Computed Tomography Proton-Dose Calculation with Scripting and Modified Hounsfield Units.

Authors:  Anthony Kassaee; Chingyun Cheng; Lingshu Yin; Wei Zou; Taoran Li; Alexander Lin; Samuel Swisher-McClure; John N Lukens; Robert A Lustig; Shannon O'Reilly; Lei Dong; Roni Hytonen Ms; Boon-Keng Kevin Teo
Journal:  Int J Part Ther       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.